CUDC-101, which targets HDACs (class I, II), EGFR and HER2, has been evaluated in combination with chemoradiation in patients with HNSCC in a phase 1 study (NCT01384799) [25]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.